{"url":"https://nivawealth.com/firms/baker-bros-advisors-158149","iapdUrl":"https://adviserinfo.sec.gov/firm/summary/158149","regulatoryAum":28147892952,"crd":"158149","secFileNumber":"801-73446","legalName":"Baker Bros. Advisors LP","displayName":"Baker Bros. Advisors","website":null,"founded":null,"organization":"Delaware limited partnership","fiscalYearEnd":"December","headquarters":{"street":"860 Washington Street, 3rd Floor","city":"New York","state":"NY","stateName":"New York","country":"United States","postalCode":"10014"},"tradeNames":["Bbi (baker Brothers Investments)"],"registration":{"secApproved":"5 March 2012","noticeFilings":null,"latestNoticeFiling":null},"staff":{"employees":60,"advisory":17,"brokerDealerReps":0,"insuranceAgents":0,"promoters":0},"aum":{"discretionary":28147892952,"discretionaryAccounts":2,"nonDiscretionary":0,"nonDiscretionaryAccounts":0,"wrapProgram":null,"nonUsClientsPct":0,"nonAumClients":0},"clientTypes":[{"label":"Pooled investment vehicles","clients":2,"regulatoryAum":28147892952}],"fees":[],"feeNotes":[],"feePrograms":[],"brochureCoverage":{"scope":"known_documents","status":"not_processed","checkedAt":null,"documents":[]},"custodians":[],"custodyNote":"Baker Bros. Advisors has custody of client assets.","otherCustodians":[],"leadership":[{"name":"Scott Lessing","title":"President, Chief Compliance Officer","crd":"4992270"},{"name":"Alexandra Toohey","title":"Chief Financial Officer","crd":"5926044"},{"name":"Julian Baker","title":"Limited Partner","crd":"2388299"},{"name":"Felix Baker","title":"Limited Partner","crd":"6019179"}],"ownership":[{"label":"Julian Baker","detail":"Limited partner in the 25% to 50% ownership band and a control person, since January 2000. Also a managing member of Baker Bros. Advisors (GP), LLC in the 50% to 75% band and a control person, since January 2000."},{"label":"Felix Baker","detail":"Limited partner in the 25% to 50% ownership band and a control person, since January 2000. Also a managing member of Baker Bros. Advisors (GP), LLC in the 50% to 75% band and a control person, since January 2000."}],"branchOffices":null,"filedOffices":{"otherThanPrincipal":1,"privateResidences":0},"listedOfficeAddresses":2,"officesByState":[{"state":"New York","offices":2,"addresses":[{"street":"860 Washington Street, 3rd Floor","city":"New York","headquarters":true},{"street":"2312 Main Street","city":"Bridgehampton"}]}],"advFacts":{"source":{"file":"ia100226.zip","asOf":"2 October 2026"},"telephone":"212-339-5600","stateRegisteredReps":0,"otherAdviserReps":0,"compensation":["A percentage of assets under management","Performance-based fees"],"activities":["Portfolio management for pooled investment vehicles (other than investment companies)"],"financialPlanningClients":null,"assetMix":[],"privateFunds":2},"sources":{"adv1FilingDate":"27 March 2026","adv1Url":"https://reports.adviserinfo.sec.gov/reports/ADV/158149/PDF/158149.pdf","brochureDate":null,"brochureUrl":null,"iapdCompiledDate":null,"retrievedDate":"15 October 2026","retrievedOn":"2026-10-15","adv1Pages":{},"brochurePages":{}},"otherBusiness":[],"faq":[{"question":"How many clients does Baker Bros. Advisors have?","answer":"Baker Bros. Advisors has 2 clients and manages $28.1 billion for them, as of March 2026.","source":"Form ADV Part 1A, Items 5.D and 5.F, filed 27 March 2026","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"What services does Baker Bros. Advisors offer?","answer":"Baker Bros. Advisors provides portfolio management for pooled vehicles.","source":"Form ADV Part 1A, Item 5.G, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"How many financial advisors does Baker Bros. Advisors have?","answer":"Baker Bros. Advisors has 0 investment adviser representatives registered with state securities authorities, out of 60 employees, and 17 perform investment advisory functions. None are registered representatives of a broker-dealer or licensed insurance agents.","source":"Form ADV Part 1A, Items 5.A and 5.B, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"Who owns Baker Bros. Advisors?","answer":"Baker Bros. Advisors’ direct owners are Julian Baker and Felix Baker, each holding 50% or less.","source":"Form ADV Part 1A, Schedules A and B, filed 27 March 2026","sourceRef":{"doc":"adv1","section":"scheduleA"}},{"question":"How does Baker Bros. Advisors get paid?","answer":"Baker Bros. Advisors is paid through a percentage of assets under management and performance-based fees. Its Form ADV lists no commissions among how it is paid.","source":"Form ADV Part 1A, Item 5.E, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}}],"holdings":{"url":"https://nivawealth.com/firms/baker-bros-advisors-158149/holdings","form":"13F-HR","periodOfReport":"2026-06-30","filedOn":"2026-08-14","filingIndexUrl":"https://www.sec.gov/Archives/edgar/data/1263508/000110465926097191/0001104659-26-097191-index.html","totalValue":19955238553,"positionCount":84,"top10Share":0.728229707021734,"top10":[{"issuer":"Incyte Corporation","titleOfClass":"COM","cusip":"45337C102","value":3487217729,"shares":30762330,"shareType":"SH","priorValue":2893664057,"priorShares":30744412},{"issuer":"BeOne Medicines Ltd.","titleOfClass":"SPONSORED ADS","cusip":"07725L102","value":2508182548,"shares":8801567,"shareType":"SH","priorValue":2613054769,"priorShares":8799053},{"issuer":"Revolution Medicines, Inc.","titleOfClass":"COM","cusip":"76155X100","value":2143111899,"shares":11443357,"shareType":"SH","priorValue":929258468,"priorShares":9555357},{"issuer":"Madrigal Pharmaceuticals, Inc.","titleOfClass":"COM","cusip":"558868105","value":1150754190,"shares":2143131,"shareType":"SH","priorValue":1121116222,"priorShares":2141701},{"issuer":"ACADIA Pharmaceuticals Inc.","titleOfClass":"COM","cusip":"004225108","value":1085696471,"shares":42912904,"shareType":"SH","priorValue":954880319,"priorShares":42896690},{"issuer":"Kymera Therapeutics, Inc.","titleOfClass":"COM","cusip":"501575104","value":992725940,"shares":8657242,"shareType":"SH","priorValue":721061686,"priorShares":8657242},{"issuer":"Insmed Incorporated","titleOfClass":"COM PAR $.01","cusip":"457669307","value":937841355,"shares":8796111,"shareType":"SH","priorValue":1213500071,"priorShares":7421111},{"issuer":"Celcuity Inc.","titleOfClass":"COM","cusip":"15102K100","value":828150159,"shares":7915792,"shareType":"SH","priorValue":903508499,"priorShares":7915792},{"issuer":"Kodiak Sciences Inc.","titleOfClass":"COM","cusip":"50015M109","value":776051487,"shares":19919186,"shareType":"SH","priorValue":759319370,"priorShares":19919186},{"issuer":"Rhythm Pharmaceuticals, Inc.","titleOfClass":"COM","cusip":"76243J105","value":622265747,"shares":5604483,"shareType":"SH","priorValue":487421887,"priorShares":5604483}],"positionsListed":84,"positions":[{"issuer":"Incyte Corporation","titleOfClass":"COM","cusip":"45337C102","value":3487217729,"shares":30762330,"shareType":"SH","priorValue":2893664057,"priorShares":30744412},{"issuer":"BeOne Medicines Ltd.","titleOfClass":"SPONSORED ADS","cusip":"07725L102","value":2508182548,"shares":8801567,"shareType":"SH","priorValue":2613054769,"priorShares":8799053},{"issuer":"Revolution Medicines, Inc.","titleOfClass":"COM","cusip":"76155X100","value":2143111899,"shares":11443357,"shareType":"SH","priorValue":929258468,"priorShares":9555357},{"issuer":"Madrigal Pharmaceuticals, Inc.","titleOfClass":"COM","cusip":"558868105","value":1150754190,"shares":2143131,"shareType":"SH","priorValue":1121116222,"priorShares":2141701},{"issuer":"ACADIA Pharmaceuticals Inc.","titleOfClass":"COM","cusip":"004225108","value":1085696471,"shares":42912904,"shareType":"SH","priorValue":954880319,"priorShares":42896690},{"issuer":"Kymera Therapeutics, Inc.","titleOfClass":"COM","cusip":"501575104","value":992725940,"shares":8657242,"shareType":"SH","priorValue":721061686,"priorShares":8657242},{"issuer":"Insmed Incorporated","titleOfClass":"COM PAR $.01","cusip":"457669307","value":937841355,"shares":8796111,"shareType":"SH","priorValue":1213500071,"priorShares":7421111},{"issuer":"Celcuity Inc.","titleOfClass":"COM","cusip":"15102K100","value":828150159,"shares":7915792,"shareType":"SH","priorValue":903508499,"priorShares":7915792},{"issuer":"Kodiak Sciences Inc.","titleOfClass":"COM","cusip":"50015M109","value":776051487,"shares":19919186,"shareType":"SH","priorValue":759319370,"priorShares":19919186},{"issuer":"Rhythm Pharmaceuticals, Inc.","titleOfClass":"COM","cusip":"76243J105","value":622265747,"shares":5604483,"shareType":"SH","priorValue":487421887,"priorShares":5604483},{"issuer":"Praxis Precision Medicines, Inc.","titleOfClass":"COM","cusip":"74006W207","value":586953158,"shares":1753198,"shareType":"SH","priorValue":564862864,"priorShares":1753198},{"issuer":"Alkermes plc","titleOfClass":"SHS","cusip":"G01767105","value":524592729,"shares":10012267,"shareType":"SH","priorValue":354033761,"priorShares":10012267},{"issuer":"Summit Therapeutics Inc.","titleOfClass":"COM","cusip":"86627T108","value":477697090,"shares":32786348,"shareType":"SH","priorValue":689974554,"priorShares":36391063},{"issuer":"GRAIL, Inc.","titleOfClass":"COM","cusip":"384747101","value":275033478,"shares":4028614,"shareType":"SH","priorValue":208198772,"priorShares":4028614},{"issuer":"AbCellera Biologics Inc.","titleOfClass":"COM","cusip":"00288U106","value":259145283,"shares":33012138,"shareType":"SH","priorValue":105663024,"priorShares":30275938},{"issuer":"Immunovant, Inc.","titleOfClass":"COM","cusip":"45258J102","value":209419027,"shares":5435220,"shareType":"SH","priorValue":135573764,"priorShares":5457881},{"issuer":"IDEAYA Biosciences, Inc.","titleOfClass":"COM","cusip":"45166A102","value":186723818,"shares":5010030,"shareType":"SH","priorValue":131497880,"priorShares":3946515},{"issuer":"Kiniksa Pharmaceuticals International, plc","titleOfClass":"ORD SHS CL A","cusip":"G52694109","value":181275420,"shares":2834643,"shareType":"SH","priorValue":136083745,"priorShares":2826246},{"issuer":"Roivant Sciences Ltd.","titleOfClass":"SHS","cusip":"G76279101","value":166928649,"shares":4716831,"shareType":"SH","priorValue":134835927,"priorShares":4867723},{"issuer":"Arrowhead Pharmaceuticals, Inc.","titleOfClass":"COM","cusip":"04280A100","value":162431742,"shares":1992783,"shareType":"SH","priorValue":124947494,"priorShares":1992783},{"issuer":"Ionis Pharmaceuticals, Inc.","titleOfClass":"COM","cusip":"462222100","value":162364274,"shares":2047727,"shareType":"SH","priorValue":153763820,"priorShares":2047727},{"issuer":"Edgewise Therapeutics, Inc.","titleOfClass":"COM","cusip":"28036F105","value":150400843,"shares":3701719,"shareType":"SH","priorValue":207142110,"priorShares":6575940},{"issuer":"Replimune Group, Inc.","titleOfClass":"COM","cusip":"76029N106","value":122271870,"shares":11045336,"shareType":"SH","priorValue":84496820,"priorShares":11045336},{"issuer":"Nurix Therapeutics, Inc.","titleOfClass":"COM","cusip":"67080M103","value":113016569,"shares":4658556,"shareType":"SH","priorValue":72207618,"priorShares":4658556},{"issuer":"Stoke Therapeutics, Inc.","titleOfClass":"COM","cusip":"86150R107","value":109176726,"shares":3336697,"shareType":"SH","priorValue":108642854,"priorShares":3336697},{"issuer":"Monte Rosa Therapeutics, Inc.","titleOfClass":"COM","cusip":"61225M102","value":105166811,"shares":4345736,"shareType":"SH","priorValue":71487357,"priorShares":4345736},{"issuer":"Immatics N.V.","titleOfClass":"SHS","cusip":"N44445109","value":96321763,"shares":9508565,"shareType":"SH","priorValue":107420259,"priorShares":10916693},{"issuer":"Denali Therapeutics Inc.","titleOfClass":"COM","cusip":"24823R105","value":96047122,"shares":3734336,"shareType":"SH","priorValue":71648544,"priorShares":3731695},{"issuer":"Crinetics Pharmaceuticals, Inc.","titleOfClass":"COM","cusip":"22663K107","value":87991820,"shares":2351465,"shareType":"SH","priorValue":85405209,"priorShares":2351465},{"issuer":"Dianthus Therapeutics, Inc.","titleOfClass":"COM","cusip":"252828108","value":83068947,"shares":852164,"shareType":"SH","priorValue":71513603,"priorShares":852164},{"issuer":"Structure Therapeutics Inc.","titleOfClass":"SPONSORED ADS","cusip":"86366E106","value":76883831,"shares":1432529,"shareType":"SH","priorValue":69047898,"priorShares":1432529},{"issuer":"Celcuity Inc.","titleOfClass":"Note  2.75% 8/1/2031","cusip":"15102KAA8","value":69158687,"shares":30750000,"shareType":"PRN","priorValue":74868563,"priorShares":30750000},{"issuer":"Rapport Therapeutics, Inc.","titleOfClass":"COM","cusip":"75383L102","value":64467240,"shares":1547090,"shareType":"SH","priorValue":48408446,"priorShares":1547090},{"issuer":"Alumis Inc.","titleOfClass":"COM","cusip":"022307102","value":56631750,"shares":2012500,"shareType":"SH","priorValue":44335375,"priorShares":2012500},{"issuer":"Prelude Therapeutics Inc.","titleOfClass":"COM","cusip":"74065P101","value":53959982,"shares":10123824,"shareType":"SH","priorValue":34623478,"priorShares":10123824},{"issuer":"Relay Therapeutics, Inc.","titleOfClass":"COM","cusip":"75943R102","value":52889110,"shares":2826783,"shareType":"SH","priorValue":11543164,"priorShares":1160117},{"issuer":"Mirum Pharmaceuticals, Inc.","titleOfClass":"COM","cusip":"604749101","value":52210293,"shares":445975,"shareType":"SH","priorValue":41199171,"priorShares":445975},{"issuer":"Bicycle Therapeutics plc","titleOfClass":"SPONSORED ADS","cusip":"088786108","value":46153914,"shares":10885357,"shareType":"SH","priorValue":50508056,"priorShares":10885357},{"issuer":"Enliven Therapeutics, Inc.","titleOfClass":"COM","cusip":"29337E102","value":45938443,"shares":905191,"shareType":"SH","priorValue":35483487,"priorShares":905191},{"issuer":"Celldex Therapeutics, Inc.","titleOfClass":"COM","cusip":"15117B202","value":44004955,"shares":1182611,"shareType":"SH","priorValue":21105536,"priorShares":665370},{"issuer":"Viridian Therapeutics, Inc.","titleOfClass":"COM","cusip":"92790C104","value":43776169,"shares":2383025,"shareType":"SH","priorValue":38566022,"priorShares":1971678},{"issuer":"Design Therapeutics, Inc.","titleOfClass":"COM","cusip":"25056L103","value":38756882,"shares":2678430,"shareType":"SH","priorValue":27514806,"priorShares":2585978},{"issuer":"Entrada Therapeutics, Inc.","titleOfClass":"COM","cusip":"29384C108","value":37335293,"shares":5072730,"shareType":"SH","priorValue":64017853,"priorShares":5072730},{"issuer":"Faeth Therapeutics, Inc.","titleOfClass":"COM","cusip":"81728A207","value":32160275,"shares":1286411,"shareType":"SH"},{"issuer":"Aktis Oncology, Inc.","titleOfClass":"COM","cusip":"01021M104","value":32112393,"shares":996351,"shareType":"SH","priorValue":17824719,"priorShares":996351},{"issuer":"Neurogene Inc.","titleOfClass":"COM","cusip":"64135M105","value":31188682,"shares":991691,"shareType":"SH","priorValue":19992491,"priorShares":991691},{"issuer":"Jade Biosciences, Inc.","titleOfClass":"COM","cusip":"008064206","value":27340066,"shares":1230426,"shareType":"SH","priorValue":23057975,"priorShares":1641137},{"issuer":"Taysha Gene Therapies, Inc.","titleOfClass":"COM SHS","cusip":"877619106","value":27272388,"shares":4004756,"shareType":"SH","priorValue":17901259,"priorShares":4004756},{"issuer":"Arcus Biosciences, Inc.","titleOfClass":"COM","cusip":"03969F109","value":26045677,"shares":844816,"shareType":"SH","priorValue":8977414,"priorShares":415621},{"issuer":"Disc Medicine, Inc.","titleOfClass":"COM","cusip":"254604101","value":25573913,"shares":349657,"shareType":"SH","priorValue":22357069,"priorShares":349657},{"issuer":"Absci Corporation","titleOfClass":"COM","cusip":"00091E109","value":24742367,"shares":2134803,"shareType":"SH","priorValue":6404409,"priorShares":2134803},{"issuer":"Generate Biomedicines, Inc.","titleOfClass":"COM SHS","cusip":"370920100","value":24016166,"shares":1423602,"shareType":"SH","priorValue":17795025,"priorShares":1423602},{"issuer":"DBV Technologies S.A.","titleOfClass":"SPONSORED ADS","cusip":"23306J309","value":23967370,"shares":1461425,"shareType":"SH","priorValue":30529168,"priorShares":1461425},{"issuer":"Xenon Pharmaceuticals Inc.","titleOfClass":"COM","cusip":"98420N105","value":22345755,"shares":370208,"shareType":"SH","priorValue":21527595,"priorShares":370208},{"issuer":"Tectonic Therapeutic, Inc.","titleOfClass":"COM","cusip":"878972108","value":20892713,"shares":607788,"shareType":"SH","priorValue":18786727,"priorShares":607788},{"issuer":"Cerus Corporation","titleOfClass":"COM","cusip":"157085101","value":18674659,"shares":6395431,"shareType":"SH","priorValue":18215188,"priorShares":10008345},{"issuer":"CytomX Therapeutics, Inc.","titleOfClass":"COM","cusip":"23284F105","value":18659348,"shares":4975826,"shareType":"SH","priorValue":23386382,"priorShares":4975826},{"issuer":"Dyne Therapeutics, Inc.","titleOfClass":"COM","cusip":"26818M108","value":18066702,"shares":813449,"shareType":"SH","priorValue":14747830,"priorShares":813449},{"issuer":"Cytokinetics, Incorporated","titleOfClass":"COM","cusip":"23282W605","value":17997836,"shares":211267,"shareType":"SH"},{"issuer":"Xencor, Inc.","titleOfClass":"COM","cusip":"98401F105","value":17743907,"shares":1102106,"shareType":"SH","priorValue":13291398,"priorShares":1102106},{"issuer":"Sionna Therapeutics, Inc.","titleOfClass":"COM","cusip":"829401108","value":17596000,"shares":400000,"shareType":"SH","priorValue":16036000,"priorShares":400000},{"issuer":"Intellia Therapeutics, Inc.","titleOfClass":"COM","cusip":"45826J105","value":15739525,"shares":930232,"shareType":"SH"},{"issuer":"Parabilis Medicines, Inc.","titleOfClass":"COM","cusip":"698955101","value":13685000,"shares":500000,"shareType":"SH"},{"issuer":"MapLight Therapeutics, Inc.","titleOfClass":"COM","cusip":"56565P103","value":13071027,"shares":364705,"shareType":"SH","priorValue":7414453,"priorShares":364705},{"issuer":"Avalyn Pharma Inc.","titleOfClass":"COM SHS","cusip":"05348Y105","value":11522000,"shares":350000,"shareType":"SH"},{"issuer":"Evommune, Inc.","titleOfClass":"COM SHS","cusip":"30054Y107","value":11261813,"shares":847390,"shareType":"SH","priorValue":19481496,"priorShares":847390},{"issuer":"BioNTech SE","titleOfClass":"SPONSORED ADS","cusip":"09075V102","value":11142086,"shares":119743,"shareType":"SH","priorValue":10642758,"priorShares":119743},{"issuer":"Tango Therapeutics, Inc.","titleOfClass":"COM","cusip":"87583X109","value":10419990,"shares":333333,"shareType":"SH"},{"issuer":"Avalo Therapeutics, Inc.","titleOfClass":"COM","cusip":"05338F306","value":10164000,"shares":550000,"shareType":"SH"},{"issuer":"Sera Prognostics, Inc.","titleOfClass":"CLASS A COM","cusip":"81749D107","value":10006669,"shares":5498170,"shareType":"SH","priorValue":11161285,"priorShares":5498170},{"issuer":"Verastem, Inc.","titleOfClass":"COM","cusip":"92337C203","value":9547471,"shares":2499338,"shareType":"SH","priorValue":3099212,"priorShares":584757},{"issuer":"Sagimet Biosciences Inc.","titleOfClass":"COM SER A","cusip":"786700104","value":7366659,"shares":952996,"shareType":"SH","priorValue":4979404,"priorShares":952996},{"issuer":"Eikon Therapeutics, Inc.","titleOfClass":"COM","cusip":"282564103","value":7249993,"shares":555555,"shareType":"SH","priorValue":5877772,"priorShares":555555},{"issuer":"LB Pharmaceuticals Inc.","titleOfClass":"COM SHS","cusip":"50180M108","value":6491000,"shares":200000,"shareType":"SH","priorValue":4932000,"priorShares":200000},{"issuer":"vTv Therapeutics, Inc.","titleOfClass":"CL A","cusip":"918385204","value":5584022,"shares":148314,"shareType":"SH","priorValue":5882133,"priorShares":148314},{"issuer":"Wave Life Sciences Ltd.","titleOfClass":"SHS","cusip":"Y95308105","value":4779527,"shares":822638,"shareType":"SH","priorValue":5964126,"priorShares":822638},{"issuer":"Protara Therapeutics, Inc.","titleOfClass":"COM STK","cusip":"74365U107","value":3711565,"shares":971614,"shareType":"SH","priorValue":5062109,"priorShares":971614},{"issuer":"TScan Therapeutics, Inc.","titleOfClass":"COM","cusip":"89854M101","value":2729375,"shares":2784792,"shareType":"SH","priorValue":2812640,"priorShares":2784792},{"issuer":"Immunome, Inc.","titleOfClass":"COM","cusip":"45257U108","value":1171934,"shares":55306,"shareType":"SH"},{"issuer":"Skye Bioscience, Inc.","titleOfClass":"COM","cusip":"83086J200","value":1092116,"shares":1575243,"shareType":"SH","priorValue":968144,"priorShares":1575243},{"issuer":"Sana Biotechnology, Inc.","titleOfClass":"COM","cusip":"799566104","value":1083586,"shares":310483,"shareType":"SH","priorValue":894191,"priorShares":310483},{"issuer":"Aligos Therapeutics, Inc.","titleOfClass":"COM","cusip":"01626L204","value":479227,"shares":83055,"shareType":"SH","priorValue":617099,"priorShares":83055},{"issuer":"Tyra Biosciences, Inc.","titleOfClass":"COM","cusip":"90240B106","value":338788,"shares":10607,"shareType":"SH","priorValue":406248,"priorShares":10607},{"issuer":"Surrozen, Inc. Warrants @ $172.50 8/11/2026 (15 FOR 1)","titleOfClass":"W EXP 8/11/2026","cusip":"86889P117","value":13750,"shares":833333,"shareType":"SH","priorValue":13333,"priorShares":833333}]},"notice":"Compiled from public SEC Form ADV filings on the dates in `sources`. Facts as filed; not a rating, ranking, or recommendation. Niva Wealth is not affiliated with this firm. Disciplinary history is deliberately not included here or on the page; the SEC publishes the complete record at the `iapdUrl` above."}